Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTAWHL)

Drug Name
AM251 Drug Info
Synonyms
AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
Cross-matching ID
PubChem CID
2125
ChEBI ID
CHEMBL285932
CAS Number
CAS 183232-66-8
TTD Drug ID
D08YQT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.17 1.18e-2 19/20 (95%) TM7SF2;CYP51A1;NSDHL;...
Amoebiasis 2.00 5.92e-3 99/102 (97.06%) CXCL2;CXCL1;CXCL3;...
Rheumatoid arthritis 1.94 1.97e-2 78/93 (83.87%) CXCL2;CXCL1;CXCL3;...
Valine, leucine and isoleucine degradation 1.94 1.48e-2 42/48 (87.5%) HMGCS1;PCCA;ABAT;...
Chemokine signaling pathway 1.93 1.18e-2 163/192 (84.9%) CXCL2;CXCL1;CXCL3;...
Retinol metabolism 1.92 1.18e-2 41/68 (60.29%) ALDH1A3;ALDH1A2;ALDH1A1;...
NF-kappa B signaling pathway 1.91 1.01e-2 90/104 (86.54%) CXCL2;CXCL1;CXCL3;...
Pertussis 1.82 1.63e-2 64/76 (84.21%) C1R;C1S;CXCL8;...
Viral protein interaction with cytokine and cytokine re... 1.82 1.45e-2 84/100 (84%) CXCL2;CXCL1;CXCL3;...
Complement and coagulation cascades 1.82 1.30e-2 76/85 (89.41%) C1R;C1S;PLAT;...
Fatty acid degradation 1.80 1.51e-2 40/43 (93.02%) ACADVL;ADH1B;ADH6;...
Histidine metabolism 1.78 1.97e-2 16/22 (72.73%) MAOA;AOC1;CNDP2;...
Legionellosis 1.78 1.82e-2 51/57 (89.47%) CXCL2;CXCL1;CXCL3;...
NOD-like receptor signaling pathway 1.77 1.77e-2 145/181 (80.11%) CXCL2;CXCL1;CXCL3;...
Leukocyte transendothelial migration 1.76 2.05e-2 90/114 (78.95%) CD99;CXCL12;ITK;...
Th1 and Th2 cell differentiation 1.75 2.07e-2 80/92 (86.96%) LCK;NFATC3;JAG1;...
Kaposi sarcoma-associated herpesvirus infection 1.74 2.44e-2 172/193 (89.12%) CXCL2;CXCL1;CXCL3;...
Epithelial cell signaling in Helicobacter pylori infect... 1.74 2.56e-2 62/70 (88.57%) CXCL2;CXCL1;CXCL3;...
Malaria 1.73 2.55e-2 44/50 (88%) CXCL8;SELE;IL6;...
beta-Alanine metabolism 1.73 2.48e-2 25/30 (83.33%) ABAT;AOC3;EHHADH;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.73 2.37e-2 79/89 (88.76%) LCK;RASGRP1;NFATC3;...
Primary bile acid biosynthesis 1.73 2.31e-2 15/17 (88.24%) AMACR;CH25H;CYP7A1;...
Apelin signaling pathway 1.71 2.52e-2 117/137 (85.4%) PLAT;CCN2;GNAI1;...
C-type lectin receptor signaling pathway 1.71 2.42e-2 93/104 (89.42%) SRC;NFATC3;IL6;...
Butanoate metabolism 1.71 2.65e-2 23/28 (82.14%) HMGCS1;ALDH5A1;ABAT;...
Th17 cell differentiation 1.68 3.19e-2 95/107 (88.79%) LCK;NFATC3;IL6;...
TNF signaling pathway 1.67 3.24e-2 103/112 (91.96%) CXCL2;CXCL1;CXCL3;...
Thyroid hormone signaling pathway 1.66 3.30e-2 112/121 (92.56%) SRC;PLN;NOTCH3;...
Human cytomegalovirus infection 1.66 3.18e-2 201/225 (89.33%) CXCL12;SRC;CXCL8;...
Terpenoid backbone biosynthesis 1.66 3.16e-2 18/22 (81.82%) HMGCS1;HMGCR;FDPS;...
Starch and sucrose metabolism -1.84 2.11e-2 25/36 (69.44%) GYG1;GBE1;GPI;...
RNA polymerase -1.86 2.11e-2 23/31 (74.19%) POLR3B;POLR2A;POLR2E;...
Ribosome biogenesis in eukaryotes -2.18 0.00e+0 52/108 (48.15%) CSNK2A1;RBM28;POP7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H